A gadolinium lawsuit is a personal injury claim brought by a patient who says a gadolinium-based contrast agent (GBCA), the dye injected before some MRI scans, caused lasting harm. If you are considering one now, the practical answer is discouraging: the older wave of cases tied to nephrogenic systemic fibrosis has been resolved, and the newer wave brought by patients with normal kidney function has largely stalled. Federal courts have refused to consolidate the newer cases, have dismissed many of them on federal preemption and statute-of-limitations grounds, and several plaintiffs’ firms have stopped taking new clients.1https://www.torhoermanlaw.com/
Who Can Still Bring a Gadolinium Claim
The litigation has moved in two waves, and which wave your situation falls into largely determines whether a claim is realistic.
The first wave involved patients with impaired kidney function who developed nephrogenic systemic fibrosis (NSF), a disease that thickens and hardens the skin, muscles, and internal organs. Those cases were consolidated into a federal multidistrict litigation (MDL No. 1909) beginning in 2008, and over 1,000 lawsuits were filed against manufacturers including Bayer and GE Healthcare. Most were resolved through settlement, and the MDL is now considered closed, with no new activity reported since November 2022. Screening protocols adopted after a 2007 FDA black box warning were effective enough that the last U.S. NSF case was reported in 2010 and the last worldwide case in 2012, so the underlying pool of new NSF plaintiffs has essentially disappeared.
The second wave involves patients with normal or near-normal kidney function who say gadolinium remained in their bodies after MRIs and produced a cluster of symptoms sometimes called gadolinium deposition disease (GDD). These are the claims prospective plaintiffs are typically asking about today, and they are the ones facing the steepest obstacles.
Why Gadolinium Deposition Disease Lawsuits Have Stalled
No MDL Consolidation
In July 2018, plaintiffs’ attorneys asked the Judicial Panel on Multidistrict Litigation to consolidate 21 federal gadolinium cases from 12 courts into a single MDL. The panel denied the request in October 2018, finding the alleged injuries were “highly plaintiff-specific” and involved multiple manufacturers and different GBCA formulations. Without consolidation, every plaintiff has to litigate alone, without shared discovery or common rulings, which sharply raises the cost and difficulty of pursuing a case.
Federal Preemption
The biggest legal obstacle is federal preemption. Manufacturers argue that because the FDA approved their labels and concluded GBCAs do not harm patients with normal kidney function, state-law claims seeking stronger warnings conflict with federal law and cannot proceed. Under Wyeth v. Levine (2009) and Merck Sharp & Dohme Corp. v. Albrecht (2019), a branded-drug maker can defeat a failure-to-warn claim by showing “clear evidence” the FDA would not have approved the label change the plaintiff says was needed.
Courts applying that framework to gadolinium cases have sided with manufacturers. In Mahnke v. Bayer Corp. (2020), the court held the failure-to-warn claim preempted because the FDA had effectively prevented the manufacturer from adding warnings about gadolinium retention toxicity in patients without kidney problems, and the research the plaintiff cited did not establish a link between retention and clinically significant adverse reactions in that group. McGrath v. Bayer HealthCare Pharm. Inc. (2019) reached a similar result, ruling that studies discussing retention without conclusions about health risks were not “newly acquired information” sufficient to overcome preemption. Design defect claims have fared no better, because major changes to an already-approved drug require prior FDA approval.
Statute of Limitations
Timing is a second common barrier. Many patients received the injections years before they connected symptoms to gadolinium, and courts have been unwilling to reset the clock to the date of that later realization. In Langara v. Bayer Corp., decided in December 2024 by the U.S. District Court for the District of Connecticut, the court dismissed all claims with prejudice. The plaintiff had symptoms and sought treatment in 2008 and 2009 after an MRI, but did not sue until years later. The court rejected the argument that the limitations period ran only from 2017, when doctors allegedly confirmed the gadolinium link, and found the 2024 filing exceeded Connecticut’s three-year limit even under the plaintiff’s own timeline. The court also declined to apply Connecticut’s savings statute to bridge a prior lawsuit dismissed in Massachusetts for lack of personal jurisdiction.
The Norris Dismissal
The highest-profile GDD case ended without recovery. Actor Chuck Norris and his wife Gena filed suit in 2017 in San Francisco County Superior Court, alleging Gena suffered cognitive deficits, body pain and burning, kidney damage, loss of energy and mobility, and difficulty breathing after receiving Bracco’s ProHance and MultiHance during three 2013 MRI scans. The complaint sought $10 million and alleged nearly $2 million in treatment costs over five years. On January 15, 2020, the Norrises voluntarily dismissed the case with prejudice in the Southern District of Texas. No settlement was paid, and each side covered its own costs. Bracco stated it “takes patient safety very seriously and stands behind the safety of all of its products.”
What the Earlier NSF Cases Produced
The first-wave litigation is what most reporting on gadolinium verdicts refers to, and it matters mainly as context. The signature outcome was the Decker case. Paul Decker, an Ohio man, developed NSF after receiving GE Healthcare’s Omniscan during a 2005 MRI. In March 2013, a jury awarded the Deckers $5 million: $4.5 million in compensatory damages to Paul and $500,000 to Karen for loss of consortium, on a failure-to-warn theory. The Sixth Circuit affirmed the verdict in October 2014, upholding the trial court’s admission of expert testimony supporting the “free gadolinium theory” of NSF causation as sufficiently supported by peer-reviewed literature and general scientific acceptance.
Beyond Decker, most NSF cases were resolved through group and individual settlements whose terms were sealed. Those outcomes do not translate into leverage for current GDD plaintiffs, because the medical and legal footing is different: NSF was tied to kidney impairment and eventually acknowledged, while GDD in patients with normal kidney function has not been.
Products and Manufacturers
GBCAs come in two chemical structures. Macrocyclic agents hold gadolinium in a more stable, cage-like configuration. Linear agents use an open-chain structure that releases gadolinium more readily. The FDA has identified Omniscan and OptiMARK as having the highest retention levels, and Dotarem, Gadavist, and ProHance as having the lowest.
The major manufacturers and products named in litigation and regulatory action include:
- Bayer: Gadavist (macrocyclic) and Magnevist (linear).
- Bracco Imaging: ProHance (macrocyclic), MultiHance (linear), and Vueway (macrocyclic).
- Guerbet: Dotarem and Elucirem (both macrocyclic), and OptiMARK (linear), which Guerbet discontinued between 2017 and 2019.
- GE Healthcare: Omniscan (linear), the agent at issue in the Decker verdict.
Symptoms and the Recognition Problem
Concern about gadolinium in patients with normal kidney function grew after 2014 research found deposits in the brains of deceased patients, followed by a 2015 Mayo Clinic autopsy study that confirmed brain-tissue retention. Later research reported gadolinium-rich nanoparticles inside human brain neurons, gadolinium in cerebrospinal fluid months after injection, and gadolinium in the urine of people with normal renal function well after their MRIs.
Dr. Richard Semelka coined the term “gadolinium deposition disease” for a cluster of persistent symptoms appearing within hours to two months after a GBCA in patients with normal or near-normal kidney function. Reported symptoms include intense burning skin pain, severe bone and joint pain, brain fog and cognitive difficulty, pins-and-needles sensations, skin thickening or discoloration, and loss of energy and mobility. Proposed diagnostic criteria require new symptoms shortly after administration, gadolinium in the body at least 30 days after exposure confirmed by urine testing, and no alternative explanation. Some researchers have proposed the more cautious label “Symptoms Associated with Gadolinium Exposure” (SAGE).
Major medical bodies have not formally recognized GDD as a distinct diagnosis, and published commentary has questioned whether it represents a genuine clinical entity. Manufacturers maintain there is no sound scientific or medical basis to conclude their products cause adverse health effects in patients with normal kidney function. That gap in medical recognition is one reason preemption arguments have succeeded: courts have found that the studies plaintiffs rely on do not establish the causal link needed to require a different warning.
Where Things Stand Now
As of 2026, gadolinium litigation is largely dormant. MDL No. 1909 is resolved. The newer GDD claims have produced no reported settlements or plaintiff verdicts. At least one prominent plaintiffs’ firm, TorHoerman Law, confirmed as of June 2026 that it is no longer accepting new clients for either NSF or GDD gadolinium claims.1https://www.torhoermanlaw.com/
A patient with normal kidney function who believes a GBCA caused injury still has the theoretical right to file an individual lawsuit. The practical hurdles are steep: no MDL to share the cost of expert work and discovery, a preemption defense that has repeatedly defeated failure-to-warn and design defect claims, statute-of-limitations problems for anyone whose exposure was years ago, and a diagnosis that major medical bodies have not endorsed. If you are weighing a claim, the first calls to make are to a product-liability attorney in your state about the limitations clock on your specific exposure date, and to your treating physician about documentation of gadolinium retention through urine testing, because both will shape whether a case is worth filing at all.